학술논문
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea
Document Type
Article
Author
Mok, Jeongha ; Lee, Myungsun ; Kim, Deog Kyeom; Kim, Ju Sang; Jhun, Byung Woo; Jo, Kyung-Wook; Jeon, Doosoo; Lee, Taehoon; Lee, Ji Yeon; Park, Jae Seuk; Lee, Seung Heon; Kang, Young Ae; Lee, Jung-Kyu; Kwak, Nakwon; Ahn, Joong Hyun; Shim, Tae Sun; Kim, Song Yee; Kim, Seungmo; Kim, Kyungjong; Seok, Kwang-Hyuk; Yoon, Soyeong; Kim, Young Ran; Kim, Jisu; Yim, Dahae; Hahn, Seokyung; Cho, Sang Nae; Yim, Jae-Joon
Source
In The Lancet 29 October-4 November 2022 400(10362):1522-1530
Subject
Language
ISSN
0140-6736